Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.50 |
| ▸ | USP2 | O75604 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034019 | 0.93 | HSD17B10 (0.53) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL484820 | 0.89 | HSD17B10 (0.49) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL27227211 | 0.89 | HSD17B10 (0.49) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL27036544 | 0.89 | HSD17B10 (0.49) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL2819024 | 0.89 | HSD17B10 (0.52) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL19717686 | 0.87 | HSD17B10 (0.50) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL4077133 | 0.86 | CYP3A4 (0.49) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL30367831 | 0.85 | HSD17B10 (0.56) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| SCHEMBL8169386 | 0.85 | HSD17B10 (0.56) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 | |
| Oxalic Acid SCHEMBL22409349 | 0.84 | HSD17B10 (0.48) | HSD17B10ALDH1A1CYP3A4USP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334325-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220396589-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-12-15 | — | — | US | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235870-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396589-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 4376/4885ALDH1A1 4520/4885CYP3A4 3727/4885 |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD17B10 23/4885ALDH1A1 78/4885CYP3A4 179/4885 |
| US-12252497-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HSD17B10 4376/4885ALDH1A1 4520/4885CYP3A4 3727/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | HSD17B10 4188/4885ALDH1A1 4355/4885CYP3A4 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.